Tango Therapeutics, Inc.
TNGX
Hisse Senetlerindeki Sıralama
#4497
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Hisse Fiyatı
$27.18
Son senkronizasyon: 2026-07-31
Piyasa Değeri
$3.38B
Değişim (1 gün)
-1.41%
Değişim (1 yıl)
213.86%
Ülke
US
Ticaret Tango Therapeutics, Inc. (TNGX)
Kategori
Healthcare
Tango Therapeutics, Inc. (TNGX) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $28.53 - 2026-07-01
Gün sonu en düşük fiyat: $10.21 - 2020-09-01
Gün sonu en düşük fiyat: $10.21 - 2020-09-01
Tango Therapeutics, Inc. için hisse fiyatı geçmişi: 2020 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | 94.33% |
| 2025 | 186.22% |
| 2024 | -66.61% |
| 2023 | 25.09% |
| 2022 | -28.88% |
| 2021 | -3.27% |
| 2020 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $535.79 | 25.64% |
US
|
|
| $183.65 | 583.99% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.43 | 8.14% |
NL
|
